RAS Inhibitor RMC ‐7977 Blocks Vascular Overgrowth of NRAS Q61R Mutant Endothelial Cells
Journal of Cellular and Molecular Medicine · 2026-08 · 30 (15)
DOI: 10.1111/jcmm.71316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 10.08.2026. Verfasst von Sara Alharbi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. Hauptthemen laut MEDLINE: Endothelial Cells, GTP Phosphohydrolases, Membrane Proteins, Mutation. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, National Institutes of Health HL156866, Lymphatic Malformation Institute.
Abstract (Originalsprache)
RAS mutations occur in patients with several types of vascular anomalies, but effective treatments remain limited. To address this need, we evaluated the RAS (ON) multi‐selective inhibitor RMC‐7977 in human endothelial cells (ECs) expressing the NRAS Q61R mutation found in kaposiform lymphangiomatosis (KLA). RMC‐7977 was evaluated using in vitro and in vivo models. Doxycycline‐inducible NRAS WT and NRAS Q61R human ECs were treated with RMC‐7977 (3.12–100 nM) or vehicle. We assessed signalling pathways, proliferation, migration, morphology, and angiopoietin‐2 (ANG‐2) production. NRAS Q61R ECs in a 3D angiogenesis assay were also treated with RMC‐7977. For in vivo studies, NRAS Q61R ECs were injected into flanks of nude mice on a doxycycline diet to generate xenografts. Mice received oral RMC‐7977 or vehicle, and xenografts were collected after 11 days. RMC‐7977 inhibited NRAS Q61R ‐induced ERK phosphorylation and reduced proliferation, migration, spindle‐like morphology, and ANG‐2 production in a dose‐dependent manner. RMC‐7977 reduced vascular area in the angiogenesis assay. In vivo, RMC‐7977 reduced xenograft weight, vascular area, and p‐ERK staining. Overall, RMC‐7977 suppressed NRAS Q61R ‐mediated signalling, aberrant EC behaviour, and ANG‐2 production in vitro and reduced vascular overgrowth in angiogenesis assays and mouse xenografts. Therefore, RMC‐7977 may be a promising therapeutic candidate for RAS‐driven vascular anomalies, including KLA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
ORCID-Profile: Sara Alharbi, Svatava Merkle, C Griffin McDaniel, George S Zaky, Andrew M Waters, Timothy D Le Cras
Förderung
- NHLBI NIH HHS
- National Institutes of Health HL156866
- Lymphatic Malformation Institute
Zitieren
APA
Alharbi, S., Merkle, S., Pastura, P., McDaniel, C. G., Zaky, G. S., Waters, A. M., & Le Cras, T. D. (2026). RAS Inhibitor RMC ‐7977 Blocks Vascular Overgrowth of NRAS Q61R Mutant Endothelial Cells. Journal of Cellular and Molecular Medicine, 30(15). https://doi.org/10.1111/jcmm.71316
Vancouver
Alharbi S, Merkle S, Pastura P, McDaniel CG, Zaky GS, Waters AM, et al. RAS Inhibitor RMC ‐7977 Blocks Vascular Overgrowth of NRAS Q61R Mutant Endothelial Cells. Journal of Cellular and Molecular Medicine. 2026;30(15). doi:10.1111/jcmm.71316
BibTeX
@article{Alharbi2026,
author = {Alharbi, Sara and Merkle, Svatava and Pastura, Patricia and McDaniel, C Griffin and Zaky, George S and Waters, Andrew M and Le Cras, Timothy D},
title = {RAS Inhibitor RMC ‐7977 Blocks Vascular Overgrowth of NRAS Q61R Mutant Endothelial Cells},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {15},
doi = {10.1111/jcmm.71316}
}
EUVIMED